Subject Index

A

Acetylcholine 467
Acoustic startle 514
Acute and prolonged effects 24
Acute dependence 500
Adinazolam 484
Adrenoceptors 58
α_2-adrenoceptors 82, 489
Adult 6-OHDA 141
Affective illness 115
Aggresion 381
Aggression 124
Alcohol 90, 247
Alcohol tolerance 258
Alcohol withdrawal 12, 237
Alcoholics 12
Alcoholism 247
Alkylating analog, BM 130 24
Alpha$_1$-adrenoceptors 240
Alprazolam 133
Amitriptyline 279, 505
Amnesia 374
Amobarbital 12
Amphetamine 66, 124, 147, 196, 271, 354
d-Amphetamine 141, 296, 381
dl-Amphetamine 119
Animal models 403
Antagonism 201, 398
Antiaggressive 40
Anticonvulsant drugs 301
Antidepressant 484
Antidepressant drugs 240, 279
Antidepressants 368
Anxiety 133, 147, 226, 426
Anxiolytics 445
Apomorphine 66, 124, 240, 271
Apparent tolerance 296
Arecoline 129
Avoidance behavior 401
Aziridinium ion 24

B

Baclofen 285
Barbiturates 445
Behavior 165
Behavioral effects 213
Behaviorally augmented tolerance 33
Behaviour 1, 467
Behavioural inhibition system 460
Benzodiazepine 226, 520
Benzodiazepine antagonism 177
Benzodiazepine antagonist 1, 520
Benzodiazepines 105, 184, 187, 267, 398, 426, 445, 514
Beta endorphin 496
Beta-adrenoceptors 240, 315
Beta$_1$-adrenoceptors 320
Beta$_2$-adrenoceptors 320
B-HT 920 58, 237
Bicuculline 285
Biochemistry 1
Bipolar 220
Bromocriptine 331

C

Caerulein 387
Calories 262
Carbamazepine 115
Catecholamine 374
Catecholamines 105, 305
Central beta-adrenoceptors 527
CER 209
Cerebrospinal fluid 387
Cheese reaction 153
Chick 58
p-Chloramphetamine 275
Chlordiazepoxide 40, 147, 177, 184, 285, 341, 460
Chlorimipramine 505
p-Chlorophenylalanine 275
Chlorpromazine 124, 346
Cholecystokinin 387
Chronic drug treatment 434
Chronic drug use 426
Chronic schizophrenics 190
Chronic treatment 279
Cichlid fish 124
Cigarette smoking 420
Circadian rhythm 493, 496
Citalopram 96, 279
Classical conditioning 354
Clenbuterol 527
Clomipramine 275
Clonazepam 301, 325
Clonidine 58, 190, 237, 374, 392
Cocaine 310
Cognition 165
Conditioned avoidance 24
Conditioned suppression 252, 305
Conditioning 247, 258, 472
Conflict test 445
Continuous reinforcement 119
Core body temperature 24
Corticotropin-releasing factor 147
Cortisol 115, 133, 496

D

Delayed-matching-to-sample 301
Depression 129
Depressive disorder 96
Desmethyldiazepam 267
Detoxication 12
DHLA 362
Diazepam 112, 165, 226, 267
3,4-Dihydroxyphenylethyleneglycol 220
Discriminative stimulus 196
Disinhibitory effects 184
DMI 141
Dopamine 12, 18, 58, 66, 196, 310, 401, 472
Dopamine agonists and antagonists 451
Dopamine receptors 158, 525
Dopaminergic agonists 331
L-dopa 374
Dorsal mundle 6-OHDA 141
Dose 141
Drug discrimination 177, 341
Drug generalization 341
Drug history 112
Drug interaction 153
DSP4 141
Dyskinesia 403
Dystonia 403

E

EEG 336
Electrophysiology 1
Electroshock-induced seizures 82
Endogenous opioids 354
Enhanced elevation 129
Epilepsy 362
Ergometrine 275
Essential fatty acid 362
Ethanol 75, 341
Ethanol tolerance 258
Ethosuximide 301, 325
Experiential factors 112
Exploration 66, 520
External inhibition 258
Extinction 209
Eyeblink 75

F

Female aggression 40
Fenfluramine 275
Fixed ratio operant response 24
Fixed ratio responding 33
Fixed-consecutive-number 325
Flavour preference 262
Flinders Sensitive and Resistant Lines 129
Fluid balance 24
Fluorescence polarization 230
Fluphenazine 480
Fluprazine 40
Fluvoxamine 279, 368
Food intake 101
Free drinking response 33

G

GABA and related receptors 315
GABAergic hypothesis of anxiolytic action 285
General signs 24
Go-no go successive discrimination 184
Growth hormone 190, 213, 331, 496
Guanfacine 237

H

Haloperidol 18
Head twitches 275
Head-twitch 320
Heart rate 75
Heroin abuse 489
^{3}H-Imipramine binding 86
Hole-board 66
Homovanillic acid 12, 63
Hot plate 514

Subject Index

A

Acetylcholine 467
Acoustic startle 514
Acute and prolonged effects 24
Acute dependence 500
Adinazolam 484
Adrenoceptors 58
α_2-adrenoceptors 82, 489
Adult 6-OHDA 141
Affective illness 115
Aggresion 381
Aggression 124
Alcohol 90, 247
Alcohol tolerance 258
Alcohol withdrawal 12, 237
Alcoholics 12
Alcoholism 247
Alkylating analog, BM 130 24
Alpha$_1$-adrenoceptors 240
Alprazolam 133
Amitriptyline 279, 505
Amnesia 374
Amobarbital 12
Amphetamine 66, 124, 147, 196, 271, 354
d-Amphetamine 141, 296, 381
dl-Amphetamine 119
Animal models 403
Antagonism 201, 398
Antiaggressive 40
Anticonvulsant drugs 301
Antidepressant 484
Antidepressant drugs 240, 279
Antidepressants 368
Anxiety 133, 147, 226, 426
Anxiolytics 445
Apomorphine 66, 124, 240, 271
Apparent tolerance 296
Arecoline 129
Avoidance behavior 401
Aziridinium ion 24

B

Baclofen 285
Barbiturates 445
Behavior 165
Behavioral effects 213
Behaviorally augmented tolerance 33
Behaviour 1, 467
Behavioural inhibition system 460
Benzodiazepine 226, 520
Benzodiazepine antagonism 177
Benzodiazepine antagonist 1, 520
Benzodiazepines 105, 184, 187, 267, 398, 426, 445, 514
Beta endorphin 496
Beta-adrenoceptors 240, 315
Beta$_1$-adrenoceptors 320
Beta$_2$-adrenoceptors 320
B-HT 920 58, 237
Bicuculline 285
Biochemistry 1
Bipolar 220
Bromocriptine 331

C

Caerulein 387
Calories 262
Carbamazepine 115
Catecholamine 374
Catecholamines 105, 305
Central beta-adrenoceptors 527
CER 209
Cerebrospinal fluid 387
Cheese reaction 153
Chick 58
p-Chloramphetamine 275
Chlordiazepoxide 40, 147, 177, 184, 285, 341, 460
Chlorimipramine 505
p-Chlorophenylalanine 275
Chlorpromazine 124, 346
Cholecystokinin 387
Chronic drug treatment 434
Chronic drug use 426
Chronic schizophrenics 190
Chronic treatment 279
Cichlid fish 124
Cigarette smoking 420
Circadian rhythm 493, 496
Citalopram 96, 279
Classical conditioning 354
Clenbuterol 527
Clomipramine 275
Clonazepam 301, 325
Clonidine 58, 190, 237, 374, 392
Cocaine 310
Cognition 165
Conditioned avoidance 24
Conditioned suppression 252, 305
Conditioning 247, 258, 472
Conflict test 445
Continuous reinforcement 119
Core body temperature 24
Corticotropin-releasing factor 147
Cortisol 115, 133, 496

D

Delayed-matching-to-sample 301
Depression 129
Depressive disorder 96
Desmethyldiazepam 267
Detoxication 12
DHLA 362
Diazepam 112, 165, 226, 267
3,4-Dihydroxyphenylethyleneglycol 220
Discriminative stimulus 196
Disinhibitory effects 184
DMI 141
Dopamine 12, 18, 58, 66, 196, 310, 401, 472
Dopamine agonists and antagonists 451
Dopamine receptors 158, 525
Dopaminergic agonists 331
L-dopa 374
Dorsal mundle 6-OHDA 141
Dose 141
Drug discrimination 177, 341
Drug generalization 341
Drug history 112
Drug interaction 153
DSP4 141
Dyskinesia 403
Dystonia 403

E

EEG 336
Electrophysiology 1
Electroshock-induced seizures 82
Endogenous opioids 354
Enhanced elevation 129
Epilepsy 362
Ergometrine 275
Essential fatty acid 362
Ethanol 75, 341
Ethanol tolerance 258
Ethosuximide 301, 325
Experiential factors 112
Exploration 66, 520
External inhibition 258
Extinction 209
Eyeblink 75

F

Female aggression 40
Fenfluramine 275
Fixed ratio operant response 24
Fixed ratio responding 33
Fixed-consecutive-number 325
Flavour preference 262
Flinders Sensitive and Resistant Lines 129
Fluid balance 24
Fluorescence polarization 230
Fluphenazine 480
Fluprazine 40
Fluvoxamine 279, 368
Food intake 101
Free drinking response 33

G

GABA and related receptors 315
GABAergic hypothesis of anxiolytic action 285
General signs 24
Go-no go successive discrimination 184
Growth hormone 190, 213, 331, 496
Guanfacine 237

H

Haloperidol 18
Head twitches 275
Head-twitch 320
Heart rate 75
Heroin abuse 489
^{3}H-Imipramine binding 86
Hole-board 66
Homovanillic acid 12, 63
Hot plate 514

Hot plate test 527
5-HT receptor antagonists 275
5-HT-antagonists 445
5-HT head-twitch 315
5-HT receptors 525
5-HT uptake 54
5-HT uptake inhibition 279
5-HT_2 receptor function 279
Human 381
Human platelets 86, 489
6-Hydroxydopamine 310
5-Hydroxytryptamine receptors 240
5-Hydroxytryptamine uptake inhibitors 240
L-5-hydroxytryptophan 320
Hyperactivity 141
Hyperdipsia 262
Hyperthermia 354
Hypophagia 262
Hypothermia 240

I

Imidazole 58
Imipramine 505
Incentive 18
Incentive value 262
Ingestive behaviors 44
Instrumental conditioning 75
Interaction 40
Isoproterenol 527

K

Kainic acid 271
Korsakoff's psychosis 374

L

Learning 165, 258
Lever press 346
Light-dark cycle 101
Light/dark periodicity 451
Limbic system 158
Lithium 209
Liver microsomes 505
Locomotion 44, 141, 158
Locomotor Activity 18, 66, 451, 520
Long-term neuroleptic therapy 190

M

Major depression 220
MAO inhibition 153
Maprotiline 96, 368
Matching law 346
Maternal aggression 40
Mecamylamine 420
Medial prefrontal cortex 310
Melperone 12
Memory 165, 426
Menstrual cycle 86
Metabolism 505
3,4-methylenedioxyamphetamine 525
3,4-methylenedioxymethamphetamine 525
Methylscopolamine 33
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 401
Methysergide 331
D-Met^2,Pro^5-enkephalinamide 331
Mianserin 109, 368
Mice 240, 275, 527
Microwaves 354
Moclobemide 153
Monkey 112
Monoamine metabolites 374
Mood 165
Morphine 44, 172, 201, 392, 472, 500
Motor activity 271, 514
Motor performance 346
Mouse 58, 82
MPTP 401
Muscarinic agonist 467
Muscarinic cholinergic receptors 33
Muscimol 285

N

NA depletion 141
N-allylnormetazocine 44
Naloxone 44, 201, 237, 354, 392, 472
Neonatal 6-OHDA 141
Neurochemistry 196
Neuroleptic 18, 480
Neuroleptic withdrawal 190
Neuroleptic-induced parkinsonism 109
Neuroleptics 63, 403
Neurology 1
Nicotine 420
Nociception (algesia) 24
Non-reward 252, 285
Noradrenaline 315
Noradrenaline uptake inhibitors 240
Noradrenergic function 133
Norepinephrine 190, 374
Nucleus accumbens 271, 451
Nucleus raphe magnus 172

O

Octopamine 305
Olfactory tubercle 451
Open-field activity 209
Operant behavior 201
Operant responding 381
Opiates 472
Opioid peptides 331
Opioid withdrawal 392
Oral activities 467
Oral surgery 226
Orienting Reflex 75
Oxazepam 12, 165
Oxotremorine 24

P

Pain modulation 527
Partial punishment 119
Pavlovian (classical) conditioning 75
Pavlovian conditioning 90
Penile erection 58
Pentobarbital 341
Peptide pharmacology 387
Performance impairment 184
Periacqueductal gray 172
Peripheral 5-HT 262
PGE_1 362
Pharmacodynamic 165
Pharmacokinetics 267
Phencyclidine 44
Phenothiazines 230
Phenytoin 301
Physiological tolerance 33
Picrotoxin 285
Pigeons 301, 325, 368
Pilocarpine 467
Pimozide 346
Pirenperone 172
Pituitary hormones 187
Placebo 247
Plasma 220
Plasma MHPG 133
Platelet membranes 230
Platelets 493
Precipitated suppression 398
Pre-frontal cortex 63
Proaggressive 40
Procyclidine 109
Prolactin 213, 331
Propranolol 252
d-Propranolol 252
l-Propranolol 252
Psychomotor performance 165, 426
Psychopathology 190
Pulse transit time 247
Punishment 252, 368

R

R(−) and S(+) apomorphine 158
R(−) and S(+) N-propylnorapomorphine 158
Rabbits 75, 336
Radial maze 460
Radioligand binding 434
Rat 18, 40, 58, 66, 101, 119, 141, 172, 177, 252, 271, 279, 285, 296, 305, 341, 346, 520
Ratbrain 267
Rate-decreasing effects 201
Ratplasma 267
Rats 54, 196, 201, 262, 451, 500, 505
Rearing 141
Receptor down regulation 434
Reference memory 460
Reinforcement 18, 296, 472
Reinforcement efficacy 346
REM latency 54
REM sleep 54
Resistance to extinction 285
Resistance to punishment 119
Response prediction 96
Response rate 346
Rhesus monkeys 392
Ritanserin 434, 445
Ro 5-4864 336
Ro 15-1788 1, 177, 336, 398, 514
Rubidium 209

S

Salbutamol 527
Schedule-controlled behavior 368, 398
Schizophrenia 362, 387, 480
Schizophrenics 496
Scopolamine 33
Sedation 520
Self-administration 310, 420
Self-stimulation 472
Sensitization 472
Serotonergic antagonists 331

Serotonin 105, 172, 493
Serotonin antagonist 434
Serotonin receptors 82
Serotonin-S_2 receptors 434
Serum corticosterone 129
Setoperone 434
Shock-induced suppression 209
Skin temperature 247
Sleep EEG 54
Spaced-responding 296
Spatial delayed alternation 112
Squirrel monkeys 398
Startle 147
Stereotypy 44
Steroid hormones 86
Stimulation-produced analgesia 172
Stimulus control 325
Stimulus discrimination 500
Stress 187, 226, 305
Strychnine 147
Successive discrimination 285
Supersensitivity 201
Supraspinal convulsions 336

T

Tail-flick test 172
Tardive dyskinesia 230
Temazepam 226
Thyramine sensitivity 153
Tolerance 63, 90, 112, 472
Training dose 341
Transport 493
Trazodone 368
Treatment 12
Triazolobenzodiazepine 484
Triazolopyridazines 105
Tricyclic antidepressants 153
Tryptophan ratio 96
L-Tryptophan 213
TSH 331
Turnover rates 105
Tyrosine ratio 96

U

Unipolar 220
Upregulation 33

V

Valproic acid 301
Variable-interval schedule 346
Voluntary ethanol consumption 101

Y

Yawning-stretching behaviour 58
Yohimbine 58, 82, 133, 237

W

Withdrawal 520
Working memory 460

Z

Zimelidine 54

Psychopharmacology

Volume 88 1986

	For North America and South America	For the rest of the world
Clinical pharmacology		
Field editors:	D. Casey, Portland	J. Gerlach, Roskilde
Advisory editors:	L.E. Hollister, Palo Alto	P. Bech, Hillerød
	R.T. Jones, San Francisco	D.P. Bobon, Liège
	D. McNair, Boston	O. Lingjaerde, Tromsø
		E.S. Paykel, Cambridge
Human experimental psychopharmacology		
Field editors:	J.O. Cole, Belmont	M. Hamilton, Leeds
Advisory editors:	C.E. Johanson, Chicago	A.R. Dabbs, Leeds
	T.O. Nelson, Seattle	I. Hindmarch, Leeds
	H.M. van Praag, New York	D.M. Warburton, Reading
Biochemical neuropharmacology, drug metabolism and pharmacokinetics		
Field editors:	F. Sulser, Nashville	J. Leysen, Beerse
Advisory editors:	I. Kopin, Bethesda	C. Braestrup, Bagsvaerd
	J. Perel, Pittsburgh	H. Heykants, Beerse
	E. Sanders-Bush, Nashville	B. Scatton, Bagneux
Behavioral pharmacology in laboratory animals		
Field editors:	H. Barry III, Pittsburgh	T.W. Robbins, Cambridge
Advisory editors:	J.B. Appel, Columbia	S.J. Cooper, Birmingham
	I. Hanin, Pittsburgh	A. Goudie, Liverpool
	H. Kalant, Toronto	B.J. Sahakian, Cambridge
	G.F. Koob, San Diego	I.P. Stolerman, London
	C. Kornetsky, Boston	
	V.G. Laties, Rochester	
	W.H. Morse, Boston	
	D.A. Overton, Philadelphia	
Preclinical psychopharmacology		
Field editors:	S.D. Glick, Albany	A.R. Green, Oxford
Advisory editors:	D.B. Goldstein, Stanford	P. Jenner, London
	J. Harvey, Iowa City	D.H. Overstreet, Bedford Park
	T.G. Heffner, Ann Arbor	R.W. Russel, Bedford Park
	K.F. Killam, Davis	J. Scheel-Krüger, Roskilde
	K.A. Miczek, Medford	

Springer International

Psychopharmacology

This journal was founded as **Psychopharmacologia** in 1959 and was renamed **Psychopharmacology** beginning with Vol. 46 (1976).

The journal has been edited by the following Managing Editors:

Vol. 1 (1959), E. Rothlin and A. Wikler; Vol. 2 (1961), E. Rothlin and H. Isbell; Vol. 3 (1962), E. Rothlin and A. Wikler; Vol. 4 (1963)–Vol. 7 (1965), J.O. Cole and E. Rothlin; Vol. 8 (1965)–Vol. 16 (1969), J.O. Cole, E. Jacobsen, M.E. Jarvik, M. Shepherd; Vol. 17 (1970), J.O. Cole, E. Jacobsen, C. Kornetzky, M. Shepherd; Vol. 18 (1970)–Vol. 27 (1972), J.O. Cole, M. Hamilton, E. Jacobsen, C. Kornetzky; Vol. 28 (1973)–Vol. 35 (1974), J.O. Cole, M. Hamilton, E. Jacobsen, C. Kornetzky, R.W. Russell; Vol. 36 (1974)–Vol. 69 (1980), H. Barry III, J.O. Cole, M. Hamilton, E. Jacobsen, R.W. Russell. Vol. 70 (1980) – Vol. 77 (1982), H. Barry III, J.O. Cole, M. Hamilton, W. Robbins, R.W. Russell.

Starting with Vol. 80 (1983) the Editors have been: H. Barry III, T.W. Robbins (Coordinating Editors), J.O. Cole, J. Gerlach, M. Hamilton, J. Leysen, F. Sulser. As of Vol. 85 (1985): H. Barry III. D.E. Casey, J.O. Cole, J. Gerlach, S.D. Glick, A.R. Green, M. Hamilton, J. Leysen, T.W. Robbins, F. Sulser.

Copyright

Submission of a manuscript implies: that the work described has not been published before (except in the form of an abstract or as part of a published lecture, review or thesis), that it is not under consideration for publication elsewhere; that its publication has been approved by all coauthors, if any, as well as by the responsible authorities at the institute where the work has been carried out; that, if and when the manuscript is accepted for publication, the authors agree to automatic transfer of the copyright to the publisher; and that the manuscript will not be published elsewhere in any language without the consent of the copyright holders.
All articles published in this journal are protected by copyright, which covers the exclusive rights to reproduce and distribute the article (e.g., as offprints), as well as all translation rights. No material published in this journal may be reproduced photographically or stored on microfilm, in electronic data bases, video disks, etc., without first obtaining written permission from the publisher.
The use of general descriptive names, trade names, trademarks, etc., in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.
While the advice and information in this journal is believed to be true and accurate at the date of its going to press, neither the authors, the editors, nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, express or implied, with respect to the material contained herein.

Special regulations for photocopies in the USA:
Photocopies may be made for personal or in-house use beyond the limitations stipulated under Section 107 or 108 of U.S. Copyright Law, provided a fee is paid. This fee is US $0.20 per page, or a minimum of US $1.00 if an article contains fewer than five pages. All fees should be paid to the Copyright Clearance Center, Inc., 21 Congress Street, Salem, MA 01970, USA, stating the ISSN 0033-3185, the volume, and the first and last page numbers of each article copied. The copyright owner's consent does not include copying for general distribution, promotion, new works, or resale. In these cases, specific written permission must first be obtained from the publisher.

Other regulations:

Authors publishing in this journal can, under certain conditions, benefit from library and photocopy fees collected by VG WORT. Authors of German nationality and those resident in the Federal Republic of Germany or Berlin (West), as well as citizens of Austria, Switzerland and member countries of the European Community, may apply to Verwertungsgesellschaft WORT, Abteilung Wissenschaft, Goethestraße 49, D-8000 München 2, for detailed information.

Printers: Universitätsdruckerei H. Stürtz AG, Würzburg
© Springer-Verlag Berlin Heidelberg 1986
Springer-Verlag GmbH & Co. KG
1000 Berlin 33
Printed in Germany

Contents

Abernethy, D.R., see Friedman, H., et al. 267

Ackenheil, M., see Müller-Spahn, F., et al. 190

Albus, M., see Müller-Spahn, F., et al. 190

Alphs, L.D., see Tamminga, C.A., et al. 387

Ambrosi, F., Ricci, S., Quartesan, R., Moretti, P., Pelicci, G., Pagliacci, C., Nicoletti, I.
Effects of acute benzodiazepine administration on growth hormone, prolactin and cortisol release after moderate insulin-induced hypoglycemia in normal women 187

Amdursky, S., see Gil-Ad, I., et al. 496

Amsterdam, J.D., Kaplan, M., Potter, L., Bloom, L., Rickels, K.
Adinazolam, a new triazolobenzodiazepine, and imipramine in the treatment of major depressive disorder 484

Amsterdam, J.D., see Winokur, A., et al. 213

Archer, T., Fredriksson, A., Jonsson, G., Lewander, T., Mohammed, A.K., Ross, S.B., Söderberg, U.
Central noradrenaline depletion antagonizes aspects of *d*-amphetamine-induced hyperactivity in the rat 141

Åsberg, M., see Modai, I., et al. 493

Baggio, G., see Ferrari, F., et al. 58

Baldessarini, R.J., see Campbell, A., et al. 158

Balsara, J.J., Bapat, T.R., Nandal, N.V., Gada, V.P., Chandorkar, A.G.
Head-twitch response induced by ergometrine in mice: Behavioural evidence for direct stimulation of central 5-hydroxytryptamine receptors by ergometrine 275

Bános, C., see Földes, J., et al. 331

Bapat, T.R., see Balsara, J.J., et al. 275

Barry, H., see O'Boyle, C.A., et al. 226

Benkelfat, C., see Poirier, M.-F., et al. 86

Benkelfat, C., see Scatton, B., et al. 220

Bercovitz, H., see Weiner, I., et al. 119

Beurs, P. de, see Møller, S.E., et al. 96

Beving, H., see Modai, I., et al. 493

Bieck, P.R., see Jedrychowski, M., et al. 529

Bloom, L., see Amsterdam, J.D., et al. 484

Booth, R.A., see Overstreet, D.H., et al. 129

Booth, R.A., see Russell, R.W., et al. 24

Borg, S., Kvande, H., Valverius, P.
Clinical conditions and central dopamine metabolism in alcoholics during acute withdrawal under treatment with different pharmacological agents 12

Botschev, C., see Müller-Spahn, F., et al. 190

Bowers Jr., M.B., Hoffmann Jr., F.J.
Homovanillic acid in caudate and pre-frontal cortex following acute and chronic neuroleptic administration 63

Bradley, C.M., Nicholson, A.N.
Behavioural responses to diazepam of drug-naive and experienced monkeys (*Macaca mulatta*) 112

Breier, A., see Charney, D.S., et al. 133

Brochet, D., Micó, J.-A., Martin, P., Simon, P.
Antinociceptive activity of beta-adrenoceptor agonist in the hot plate test in mice 527

Buckland, C., Mellanby, J., Gray, J.A.
The effects of compounds related to γ-aminobutyrate and benzodiazepine receptors on Behavioural responses to anxiogenic stimuli in the rat: Extinction and successive discrimination 285

Burton, M.J., see Montgomery, A.M.J. 262

Butler, R., see Vaddadi, K.S., et al. 362

Campbell, A., Baldessarini, R.J., Teicher, M.H., Neumeyer, J.L.
Behavioral effects of apomorphine isomers in the rat: Selective locomotor-inhibitory effects of S(+)N-*n*-propylnorapomorphine 158

Cervo, L., see Woolverton, W.L. 196

Chandorkar, A.G., see Balsara, J.J., et al. 275

Channell, S.L., see Salamone, J.D., et al. 467

Charney, D.S., Breier, A., Jatlow, P.I., Heninger, G.R.
Behavioral, biochemical, and blood pressure responses to alprazolam in healthy subjects: Interactions with Yohimbine 133

Chase, T.N., see Tamminga, C.A., et al. 387

Cherek, D.R., Steinberg, J.L., Kelly, T.H., Robinson, D.E.
Effects of *d*-amphetamine on human aggressive behavior 381

Chou, C.K., see Lai, H., et al. 354

Clark, R., see Poling, A., et al. 301

Cohen, B.M., see Zubenko, G.S. 230

Cohen, Stuart, M.H. see Møller, S.E., et al. 96

Cole, S.O., Michaleski, A.
Dose-dependent impairment in the performance of a go-no go successive discrimination by chlordiazepoxide 184

Colpaert, F.C., see Meert, T.F. 445

Cools, A.R.
Mesolimbic dopamine and its control of locomotor activity in rats: differences in pharmacology and light/dark periodicity between the olfactory tubercle and the nucleus accumbens 451

Coulon, J.F., see Ennaceur, A., et al. 305

Crocker, A.D., see Russell, R.W., et al. 24

Cullen, J.H., see O'Boyle, C.A., et al. 226

Dana, R., see Overstreet, D.H., et al. 129

David, J.C., see Ennaceur, A., et al. 305

Delacour, J., see Ennaceur, A., et al. 305

Dennis, T., see Scatton, B., et al. 220

De Vry, J., Slangen, J.L.
Effects of chlordiazepoxide training dose on the mixed agonist-antagonist properties of benzodiazepine receptor antagonist Ro 15-1788, in a drug discrimination procedure 177

De Vry, J., Slangen, J.L.
Effects of training dose on discrimination and cross-generalization of chlordiazepoxide, pentobarbital and ethanol in the rat 341

Dickerman, Z., see Gil-Ad, I., et al. 496

Ehlert, F.J., see Russell, R.W., et al. 33

Eichler, H.G., see Korn, A., et al. 153

Endsley, B., see Picker, M., et al. 325

Ennaceur, A., Coulon, J.F., Delacour, J., David, J.C.
High sensitivity of brain octopamine levels to stress 305

Feldman, R.S., see McElroy, J.F., et al. 105

Feldon, J., see Weiner, I., et al. 119

Ferrari, F., Martinelli, R., Baggio, G.
Imidazole has similar behavioural effects to yohimbine 58

Fibiger, H.C., see Martin-Iverson, M.T., et al. 310

File, S.E., Pellow, S.
Intrinsic actions of the benzodiazepine receptor antagonist Ro 15-1788 1

File, S.E., see Lister, R.G. 520

Fischbach, R., see Korn, A., et al. 153

Földes, J., Váradi, A., Gara, Á., Bános, C., Vargha, P., Török, K., Székely, J.I.
Effects of methysergide, bromocriptine and naloxone on prolactin, growth hormone and TSH release induced by D-Met^2,Pro^5-enkephalinamide in man 331

Franklin, K.B.J., see Hand, T.H. 472

Fredriksson, A., see Archer, T., et al. 141

Friedman, H., Abernethy, D.R., Greenblatt, D.J., Shader, R.I.
The pharmacokinetics of diazepam and desmethyldiazepam in rat brain and plasma 267

Friis, T., see Korsgaard, S. 109

Gada, V.P., see Balsara, J.J., et al. 275

Galzin, A.-M., see Poirier, M.-F., et al. 86

Gara, Á., see Földes, J., et al. 331

García-Sevilla, J.A., Ugedo, L., Ulibarri, I., Gutierrez, M.
Heroin increases the density and sensitivity of platelet α_2-adrenoceptors in human addicts 489

Gasic, S., see Korn, A., et al. 153

Gay, C., see Scatton, B., et al. 220

Geller, A.M., see Lucki, I., et al. 426

Geyer, M.A., see Swerdlow, N.R., et al. 147

Ghoneim, M.M., see Mewaldt, S.P., et al. 165

Gil-Ad, I., Dickerman, Z., Amdursky, S., Laron, Z.
Diurnal rhythm of plasma beta endorphin, cortisol and growth hormone in schizophrenics as compared to control subjects 496

Gilleard, C.J., see Vaddadi, K.S., et al. 362

Glennon, R.A., see Lyon, R.A., et al. 525

Gold, P.W., see Rubinow, D.R., et al. 115

Gommeren, W., see Leysen, J.E., et al. 434

Gowans, G.C., see Grilly, D.M. 500

Gray, J.A., see Buckland, C., et al. 285

Gray, J.A., see Salmon, P. 252

Green, S., see Hodges, H. 460

Greenberg, B.D., Segal, D.S.
Evidence for multiple opiate receptor involvement in different phencyclidine-induced unconditioned behaviors in rats 44

Greenblatt, D.J., see Friedman, H., et al. 267

Griffiths, R.R., see Nemeth-Coslett, R., et al. 420

Grilly, D.M., Gowans, G.C.
Acute morphine dependence: Effects observed in shock and light discrimination tasks 500

Gutierrez, M., see García-Sevilla, J.A., et al. 489

Guy, A.W., see Lai, H., et al. 354

György, L., see Ludvig, N., et al. 82

Hand, T.H., Franklin, K.B.J.
Associative factors in the effects of morphine on self-stimulation 472

Handley, S.L., Singh, L.
The modulation of head-twitch behaviour by drugs acting on beta-adrenoceptors: evidence for the involvement of both beta$_1$ and beta$_2$-adrenoceptors 320

Handley, S.L., see Singh, L., et al. 315

Harris, D., see O'Boyle, C.A., et al. 226

Hawes, E.M., see Marder, S.R., et al. 480

Heaton, J.C.P., see Singh, L., et al. 315

Heninger, G.R., see Charney, D.S., et al. 133

Henningfield, J.E., see Nemeth-Coslett, R., et al. 420

Hernández, L.L., Powell, D.A.
Ethanol enhancement of Pavlovian conditioning: Comparison with instrumental conditioning 75

Heyman, G.M., Kinzie, D.L., Seiden, L.S.
Chlorpromazine and pimozide alter reinforcement efficacy and motor performance 346

Hill, S.Y., see Reyes, R.B., et al. 54

Hines, G.
Effects of lithium and rubidium on shock-induced changes in open-field activity 209

Hinrichs, J.V., see Mewaldt, S.P., et al. 165

Hodges, H., Green, S.
Effects of chlordiazepoxide on cued radial maze performance in rats 460

Hoffmann Jr., F.J.., see Bowers Jr., M.B. 63

Hölzl, G., see Krüger, R., et al. 505

Horita, A., see Lai, H., et al. 354

Høpfner Petersen, H.E., see Møller, S.E., et al. 96

Hubbard, J.W., see Marder, S.R., et al. 480

Hwa, J.J., see Russell, R.W., et al. 33

Iso, H.
Voluntary ethanol consumption in the absence of hunger and thirst drives 101

Iversen, S.D., see Salamone, J.D., et al. 467

Janowsky, D.S., see Overstreet, D.H., et al. 129

Janssen, P.A.J., see Leysen, J.E., et al. 434

Jarvis, M.F., see Wagner, G.C., et al. 401

Jatlow, P.I., see Charney, D.S., et al. 133

Jedrychowski, M., Nilsson, E., Bieck, P.R.
Metabolic fate of CGS 8216, a benzodiazepine receptor antagonist, in rat and in man 529

Jenden, D.J., see Russell, R.W., et al. 24

Jenner, P., see Rupniak, N.M.J., et al. 403

Jonsson, G., see Archer, T., et al. 141

Kafetzopoulos, E.
Effects of amphetamine and apomorphine on locomotor activity after kainic acid lesion of the nucleus accumbens septi in the rat 271

Kaplan, M., see Amsterdam, J.D., et al. 484

Katz, J.L.
Effects of clonidine and morphine on opioid withdrawal in rhesus monkeys 392

Keith, A.B., see Sahgal, A. 131

Kelley, A.E., Winnock, M., Stinus, L.
Amphetamine, apomorphine and investigatory behavior in the rat: Analysis of the structure and pattern of responses 66

Kelly, T.H., see Cherek, D.R., et al. 381

Kinzie, D.L., see Heyman, G.M., et al. 346

Koob, G.F., see Swerdlow, N.R., et al. 147

Korn, A., Eichler, H.G., Fischbach, R., Gasic, S.
Moclobemide, a new reversible MAO inhibitor – interaction with tyramine and tricyclic antidepressants in healthy volunteers and depressive patients 153

Korsgaard, S., Friis, T.
Effects of mianserin in neuroleptic-induced parkinsonism 109

Krüger, R., Hölzl, G., Kuss, H.J., Schefold, L.
Comparison of the metabolism of the three antidepressants amitriptyline, imipramine, and chlorimipramine in vitro rat liver microsomes 505

Kulkarni, S.K., see Parale, M.P. 237

Kupfer, D.J., see Reyes, R.B., et al. 54

Kuss, H.J., see Krüger, R., et al. 505

Kvande, H., see Borg, S., et al. 12

Lai, H., Horita, A., Chou, C.K., Guy, A.W.
Effects of low-level microwave irradiation on amphetamine hyperthermia are blockable by naloxone and classically conditionable 354

Lalies, M.D., see Salamone, J.D., et al. 467

Lamb, R.J., McMillan, D.E.
The effects of some putative antidepressant agents on the schedule-controlled behavior of the pigeon 368

Langer, S.Z., see Poirier, M.-F., et al. 86

Laron, Z., see Gil-Ad, I., et al. 496

Leibold, L., see Picker, M., et al. 325

Leijnse-Ybema, H.J., see Møller, S.E., et al. 96

Lewander, T., see Archer, T., et al. 141

Leysen, J.E., Gompel, P. Van., Gommeren, W., Woestenborghs, R., Janssen, P.A.J.
Down regulation of serotonin-S_2 receptor sites in rat brain by chronic treatment with the serotonin-S_2 antagonists: ritanserin and setoperone 434

Lindberg, N.D., see Winokur, A., et al. 213

Lister, R.G., File, S.E.
A late-appearing benzodiazepine-induced hypoactivity that is not reversed by a receptor antagonist 520

Littman, R.L., see Tamminga, C.A., et al. 387

Loo, H., see Scatton, B., et al. 220

Lucantoni, D., see Massotti, M. 336

Lucki, I., Rickels, K., Geller, A.M.
Chronic use of benzodiazepines and psychomotor and cognitive test performance 426

Lucki, I., see Winokur, A., et al. 213

Ludvig, N., György, L., Vizi, E.S.
Evidence that serotonin receptors are involved in the anticonvulsant effect of yohimbine in mice 82

Lyon, R.A., Glennon, R.A., Titeler, M.
3,4-Methylenedioxymethamphetamine (MDMA): Stereoselective interactions at brain 5-HT_1 and 5-HT_2 receptors 525

Mair, R.G., McEntee, W.J.
Cognitive enhancement in Korsakoff's psychosis by clonidine: A comparison with L-Dopa and Ephedrine 374

Malmgren, R., see Modai, I., et al. 493

Marder, S.R., Hawes, E.M., Van Putten, T., Hubbard, J.W., McKay, G., Mintz, J., May, P.R.A., Midha, K.K.
Fluphenazine plasma levels in patients receiving low and conventional doses of fluphenazine decanoate 480

Marsden, C.D., see Rupniak, N.M.J., et al. 403

Martin, P., see Brochet, D., et al. 527

Martinelli, R., see Ferrari, F., et al. 58

Martin-Iverson, M.T., Szostak, C., Fibiger, H.C.
6-Hydroxydopamine lesions of the medial prefrontal cortex fail to influence intravenous self-administration of cocaine 310

Massotti, M., Lucantoni, D.
The peripheral benzodiazepine receptor ligand Ro 5-4864 induces supraspinal convulsions in rabbits. Reversal by the central benzodiazepine antagonist Ro 15-1788 336

May, P.R.A., see Marder, S.R., et al. 480

Mazela, H., see Pawlowski, L. 240

McElroy, J.F., Feldman, R.S., Meyer, J.S.
A comparison between chlordiazepoxide and CL 218,872, a synthetic non-benzodiazepine ligand for benzodiazepine receptors, on serotonin and catecholamine turnover in brain 105

McEntee, W.J., see Mair, R.G. 374

McKay, G., see Marder, S.R., et al. 480

McLamb, R.L., see Walsh, T.J., et al. 514

McMillan, D.E., see Lamb, R.J. 368

Meert, T.F., Colpaert, F.C.
The shock probe conflict procedure. A new assay responsive, to benzodiazepines, barbiturates and related compounds 445

Mellanby, J., see Buckland, C., et al. 285

Melzacka, M., see Pawlowski, L. 279

Mewaldt, S.P., Ghoneim, M.M., Hinrichs, J.V.
The behavioral actions of diazepam and oxazepam are similar 165

Meyer, J.S., see McElroy, J.F., et al. 105

Michaleski, A., see Cole, S.O. 184

Micó, J.-A., see Brochet, D., et al. 527

Midha, K.K., see Marder, S.R., et al. 480

Mindham, R.H.S., see Vaddadi, K.S., et al. 362

Mintz, J., see Marder, S.R., et al. 480

Møller, S.E., Beurs, P. de, Timmermann, L., Tan, B.K., Leijnse-Ybema, H.J., Cohen Stuart, M.H., Høpfner-Petersen, H.E.
Plasma tryptophan and tyrosine ratios to competing amino acids in relation to antidepressant response to citalopram and maprotiline. A preliminary study 96

Modai, I., Malmgren, R., Åsberg, M., Beving, H.
Circadian rhythm of serotonin transport in human platelets 493

Mohammed, A.K., see Archer, T., et al. 141

Montgomery, A.M.J., Burton, M.J.
Effects of peripheral 5-HT on consumption of flavoured solutions 262

Moretti, P., see Ambrosi, F., et al. 187

Mos, J., see Olivier, B., et al. 40

Müller-Spahn, F., Ackenheil, M., Albus, M., Botschev, C., Naber, D., Welter, D.
Neuroendocrine effects of clonidine in chronic schizophrenic patients under long-term neuroleptic therapy and after drug withdrawal: Relations to psychopathology 190

Munro, A.D.
The effects of apomorphine, *d*-amphetamine and chlorpromazine on the agressiveness of isolated *Aequidens pulcher* (Teleostei, Cichlidae) 124

Naber, D., see Müller-Spahn, F., et al. 190

Nandal, N.V., see Balsara, J.J., et al. 275

Nathan, P.E., see Shapiro, A.P. 90

Nemeth-Coslett, R., Henningfield, J.E., O'Keeffe, M.K., Griffiths, R.R.
Effects of mecamylamine on human cigarette smoking and subjective ratings 420

Neumeyer, J.L., see Campbell, A., et al. 158

Newlin, D.B.
Conditioned compensatory response to alcohol placebo in humans 247

Nicholson, A.N., see Bradley, C.M. 112

Nicoletti, I., see Ambrosi, F., et al. 187

Nilsson, E., see Jedrychowski, M., et al. 529

O'Boyle, C.A., Harris, D., Barry, H., Cullen, J.H.
Differential effect of benzodiazepine sedation in high and low and anxious patients in a "real life" stress setting 226

O'Keeffe, M.K., see Nemeth-Coslett, R., et al. 420

Olivier, B., Mos, J., Oorschot, R. van
Maternal aggression in rats: Lack of interaction between chlordiazepoxide and fluprazine 40

Oorschot, R. van, see Olivier, B., et al. 40

Overstreet, D.H., Booth, R.A., Dana, R., Risch, S.C., Janowsky, D.S.
Enhanced elevation of corticosterone following arecoline administration to rats selectively bred for increased cholinergic function 129

Pagliacci, C., see Ambrosi, F., et al. 187

Parale, M.P., Kulkarni, S.K.
Studies with α_2-adrenoceptor agonists and alcohol abstinence syndrome in rats 237

Paul, D., Phillips, A.G.
Selective effects of pirenperone on analgesia producted by morphine or electrical stimulation at sites in the nucleus raphe magnus and periaqueductal gray 172

Pawlowski, L., Mazela, H.
Effects of antidepressant drugs, selective noradrenaline-or 5-hydroxytryptamine uptake inhibitors, on apomorphine-induced hypothermia in mice 240

Pawlowski, L., Melzacka, M.
Inhibition of head twitch response to quipazine in rats by chronic amitriptyline but not fluvoxamine or citalopram 279

Pelicci, G., see Ambrosi, F., et al. 187

Pellow, S., see File, S.E. 1

Phillips, A.G., see Paul, D. 172

Phillips, J., see Winokur, A., et al. 213

Picker, M., Leibold, L., Endsley, B., Poling, A.
Effects of clonazepam and ethosuximide on the responding of pigeons under a fixed-consecutive-number schedule with and without an external discriminative stimulus 325

Picker, M., see Poling, A., et al. 301

Poirier, M.-F., Benkelfat, C., Galzin, A.-M., Langer, S.Z.
Platelet ^{3}H-imipramine binding and steroid hormones serum concentrations during the menstrual cycle 86

Poirier-Littre, M.-F., see Scatton, B., et al. 220

Polder, D.V., see Poling, A., et al. 301

Poling, A., Picker, M., Polder, D.V., Clark, R.
Chronic effects of ethosuximide, phenytoin, clonazepam, and valproic acid on the delayed-matching-to-sample performance of pigeons 301

Poling, A., see Picker, M., et al. 325

Post, R.M., see Rubinow, D.R., et al. 115

Potter, L., see Amsterdam, J.D., et al. 484

Powell, D.A., see Hernández, L.L. 75

Quartesan, R., see Ambrosi, F., et al. 187

Rea, P.J., see Singh, L., et al. 315

Reyes, R.B., Hill, S.Y., Kupfer, D.J.
Effects of repeated zimelidine administration on sleep parameters in the rat 54

Ricci, S., see Ambrosi, F., et al. 187

Rickels, K., see Amsterdam, J.D., et al. 484

Rickels, K., see Lucki, I., et al. 426

Risch, S.C., see Overstreet, D.H., et al. 129

Robinson, D.E., see Cherek, D.R., et al. 381

Ross, S.B., see Archer, T., et al. 141

Rubin, J.G., see Wagner, G.C., et al. 401

Rubinow, D.R., Post, R.M., Gold, P.W., Uhde, T.W.
Effect of carbamazepine on mean urinary free cortisol excretion in patients with major affective illness 115

Rupniak, N.M.J., Jenner, P., Marsden, C.D.
Acute dystonia induced by neuroleptic drugs 403

Russell, R.W., Crocker, A.D., Booth, R.A., Jenden, D.J.
Behavioral and physiological effects of an aziridinium analog of oxotremorine (BM 130) 24

Russell, R.W., Ehlert, F.J., Hwa, J.J.
Relation between behaviorally augmented tolerance and upregulation of muscarinic receptors in the CNS: Effects of chronic administration of scopolamine 33

Sahgal, A., Keith, A.B.
Locomotor activity and neurotensin: Resolution of discrepancies in effects? 131

Salamone, J.D.
Different effects of haloperidol and extinction on instrumental behaviours 18

Salamone, J.D., Lalies, M.D., Channell, S.L., Iversen, S.D.
Behavioural and pharmacological characterization of the mouth movements induced by muscarinic agonists in the rat 467

Salmon, P., Gray, J.A.
Effects of propranolol on conditioned suppression, discriminated punishment and discriminated non-reward in the rat 252

Scatton, B., Loo, H., Dennis, T., Benkelfat, C., Gay, C., Poirier-Littre, M.-F.
Decrease in plasma levels of 3,4-dihydroxyphenylethyleneglycol in major depression 220

Schefold, L., see Krüger, R., et al. 505

Sdao-Jarvie, K., see Siegel, S. 258

Segal, D.S., see Greenberg, B.D. 44

Seiden, L.S., see Heyman, G.M., et al. 346

Shader, R.I., see Friedman, H., et al. 267

Shapiro, A.P., Nathan, P.E.
Human tolerance to alcohol: The role of Pavlovian conditioning processes 90

Siegel, S., Sdao-Jarvie, K.
Attenuation of ethanol tolerance by a novel stimulus 258

Simon, P., see Brochet, D., et al. 527

Singh, L., Heaton, J.C.P., Rea, P.J., Handley, S.L.
Involvement of noradrenaline in potentiation of the head-twitch response by GABA related drugs 315

Singh, L., see Handley, S.L. 320

Slangen, J.L., see De Vry, J. 177

Slangen, J.L., see De Vry, J. 341

Smith, J.B.
Effects of chronically administered *d*-amphetamine on spaced responding maintained under multiple and single-component schedules 296

Söderberg, U., see Archer, T., et al. 141

Spealman, R.D.
Disruption of schedule-controlled behavior by Ro 15-1788 one day after acute treatment with benzodiazepines 398

Steinberg, J.L., see Cherek, D.R., et al. 381

Stinus, L., see Kelley, A.E., et al. 66

Swerdlow, N.R., Geyer, M.A., Vale, W.W., Koob, G.F.
Corticotropin-releasing factor potentiates acoustic startle in rats: Blockade by chlordiazepoxide 147

Székely, J.I., see Földes, J., et al. 331

Szostak, C., see Martin-Iverson, M.T., et al. 310

Tamminga, C.A., Littman, R.L., Alphs, L.D., Chase, T.N., Thaker, G.K., Wagman, A.M.
Neuronal Cholecystokinin and Schizophrenia: pathogenic and therapeutic studies 387

Tan, B.K., see Møller, S.E., et al. 96

Teicher, M.H., see Campbell, A., et al. 158

Thaker, G.K., see Tamminga, C.A., et al. 387

Tilson, H.A., see Walsh, T.J., et al. 514

Timmermann, L., see Møller, S.E., et al. 96

Titeler, M., see Lyon, R.A., et al. 525

Török, K., see Földes, J., et al. 331

Ugedo, L., see García-Sevilla, J.A., et al. 489

Uhde, T.W., see Rubinow, D.R., et al. 115

Ulibarri, I., see García-Sevilla, J.A., et al. 489

Vaddadi, K.S., Gilleard, C.J., Mindham, R.H.S., Butler, R.
A controlled trial of prostaglandin E 1 precursor in chronic neuroleptic resistant schizophrenic patients 362

Vale, W.W., see Swerdlow, N.R., et al. 147

Valverius, P., see Borg, S., et al. 12

Van Gompel, P., see Leysen, J.E., et al. 434

Van Putten, T., see Marder, S.R., et al. 480

Váradi, A., see Földes, J., et al. 331

Vargha, P., see Földes, J., et al. 331

Vizi, E.S., see Ludvig, N., et al. 82

Wagman, A.M., see Tamminga, C.A., et al. 387

Wagner, G.C., Jarvis, M.F., Rubin, J.G.
L-Dopa reverses the effects of MPP^+ toxicity 401

Walsh, T.J., McLamb, R.L., Tilson, H.A.
A comparison of the effects of RO15,1788 and chlordiazepoxide on hot-plate latencies, acoustic startle, and locomotor activity 514

Weiner, I., Bercovitz, H., Feldon, J.
Amphetamine does not affect the partial punishment effect (PPE) 119

Welter, D., see Müller-Spahn, F., et al. 190

Winnock, M., see Kelley, A.E., et al. 66

Winokur, A., Lindberg, N.D., Lucki, I., Phillips, J., Amsterdam, J.D.
Hormonal and behavioral effects associated with intravenous L-tryptophan administration 213

Woestenborghs, R., see Leysen, J.E., et al. 434

Woolverton, W.L., Cervo, L.
Effects of central dopamine depletion on the *d*-amphetamine discriminative stimulus in rats 196

Young, A.M.
Effects of acute morphine pretreatment on the rate-decreasing and antagonist activity of naloxone 201

Zubenko, G.S., Cohen, B.M.
A cell membrane correlate of tardive dyskinesia in patients treated with phenothiazines 230